BT Slingsby, Renalys Pharma CEO
Renalys raises $37.8M to take Travere's kidney disease drug into Phase 3 trial in Japan
Japanese biotech Renalys Pharma has raised $37.8 million (¥6 billion) in a Series A round to work on an approval in Japan for the drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
